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EKPRESI RANKL SEBAGAI PETANDA PROGNOSTIK DALAM 
PENYAKIT “GIANT CELL TUMOUR” TULANG TAHAP III 
 
Dr Nur Sabrina Abdul Ghani 
MMed Orthopaedic Surgery 
 
Department of Orthopaedics 
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Health Campus, 16150 Kelantan, Malaysia 
 
Pengenalan: Penyakit “Giant cell Tumour” tulang adalah barah tulang yang  
bersifat agresif dan mempunyai kecenderungan untuk bertukar menjadi malignan. Ia 
mengandungi pelbagai jenis sel termasuk mononuclear sel stroma yang bersifat tidak 
stabil dan komponen reaktif iaitu monosit dan osteoklas. Di kalangan penduduk Asia 
termasuk Malaysia, ia dilaporkan lebih agresif dan mempunyai kadar yang lebih tinggi 
untuk merebak ke paru-paru. Sehingga kini, masih terdapat banyak keraguan dalam 
menjangka tahap kecenderungan untuk berulang dan perebakan ke paru-paru.  
 
Objektif: Kajian ini bertujuan untuk menentukan keberkesanan ekspresi RANKL 
sebagai petanda prognostik dalam menjangka risiko untuk penyakit berulang dan 
perebakan ke paru-paru. 
 
 xiv 
Bahan dan Kaedah: Kajian dan penilaian ekspresi RANKL secara 
“immunohistochemical” dijalankan ke atas 39 pesakit barah GCT tahap III. Terdapat 21 
pesakit lelaki dan 18 pesakit perempuan dan purata umur adalah 36.2 tahun, di mana 
umur pesakit adalah dari 11 tahun hingga 66 tahun. Majoriti pesakit adalah berbangsa 
Melayu (85%) diikuti bangsa Cina (15%). Penyakit ini kebanyakannya terjadi di sekitar 
sendi lutut (46.2%) diikuti bahagian pergelangan tangan (17.9%). 35 daripada 39 (90%) 
pesakit telah menjalani pembedahan “wide resection” manakala 3 orang pesakit lagi 
menjalani reseksi intralesional dan hanya seorang pesakit telah menjalani amputasi tulang 
metakarpal.  
Terdapat 10% daripada pesakit mengalami ulangan penyakit manakala 20% pula 
mengalami perebakan penyakit ke paru-paru. Sebanyak 5% mengalami kedua-dua 
masalah ulangan penyakit dan perebakan penyakit ke paru-paru. Antibodi poliklonal   
RANKL dari Santa Cruz Bioteknologi, telah digunakan untuk proses immunostaining. 
Pemarkahan dibuat berdasarkan sel yang positif bagi RANKL berlatar belakangkan 1000 
sel stroma mononuklear. Semua data telah dianalsis menggunakan PASW versi 18.0. 
 
Keputusan: Ekspresi RANKL dinilai berdasarkan peratus ekspresi (<25%, 25%-
75%, >75%), kekuatan pewarnaan (1 hingga 3) dan jumlah markah bagi kedua-dua nilai 
(1-2= lemah, 3-4= sederhana, 5-6= kuat).  Ekspresi RANKL didapati positif  >75% pada 
82% daripada jumlah sampel. Manakala, dari segi kekuatan pewarnaan, 48% mendapat 
markah 2 dan hanya 23% mendapat markah 3. 66.6% menunjukkan ekspresi RANKL 
yang kuat. Purata RANKL berdasarkan peratus pewarnaan, kekuatan pewarnaan dan 
jumlah kedua-dua nilai ialah  2.79 (SD 0.47), 1.95 (SD 0.72) dan 4.77 (SD 0.99). Nilai 
 xv 
purata ekspresi RANKL dari segi peratus pewarnaan adalah signifikan secara statistik 
dalam kumpulan kajian yang membandingkan penyakit berulang (p=0.009). 
 
Kesimpulan: Ekspresi RANKL mungkin boleh digunakan sebagai parameter 
untuk menjangka risiko penyakit barah GCT tulang terhadap kecenderungan untuk 
berulang tetapi tidak untuk risko perebakan ke  paru- paru.  
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RANKL EXPRESSION AS A PROGNOSTIC MARKER IN STAGE 
III GIANT CELL TUMOUR OF THE BONE  
 
Dr Nur Sabrina Abdul Ghani 
MMed Orthopaedic Surgery 
 
Department of Orthopaedics 
School of Medical Sciences, Universiti Sains Malaysia 
Health Campus, 16150 Kelantan, Malaysia 
 
Introduction: Giant cell tumour of bone is an aggressive benign bone tumor 
composed of unstable spindle shaped neoplastic mononuclear stromal cells and reactive 
components osteoclast like giant cells. GCT in Asian population including Malaysia, 
presented with more aggressive tumour and higher rate of lung metastasis. Although 
numerous attempts have been made to predict the behavior of GCT, there are no definite 
biological or histological parameters to determine the prognosis or aggressiveness of this 
lesion.  
 
Objectives: The aim of this study is to determine the presence of RANKL 
activity in aggressive type (stage III) GCT and its effectiveness as a prognostic marker in 
predicting risk of local recurrence and lung metastasis in GCT of bone. 
 
 xvii 
Material and method: We evaluated 39 cases of stage III GCT of bone for 
RANKL expression using immunohistochemical staining. There were 21 males and 18 
females patients and the mean age was 36.2 (ranged between 11 to 66 years old). 
Majority of the patients were Malays (85%) followed by Chinese (15%). 46.2% of the 
tumour occurred at a knee region followed by distal radius (17.9%). 35 out of 39 (90%) 
patients were treated with wide resection, 3 by intralesional resection and 1 cases of 
metacarpal GCT with extensive soft tissue involvement were treated by rays amputation. 
10% of cases had local recurrence and 20% presented with or eventually developed lung 
metastasis. 5% of the cases presented with local recurrence and lung metastasis. 
Expression of RANKL was evaluated by immuno-histochemical staining techniques 
using the rabbit polyclonal antibody RANKL representing full-length RANKL human 
origin from Santa Cruz Biotechnology. The scoring was done by counting the positively 
stained cell in the background of 1000 mononuclear stromal cells. Data was analyzed 
using PASW version 18.0. 
 
Result: RANKL expressions were evaluated by percentage of expression (<25%, 
25%-75%, >75%), staining intensity (1 to 3) and final score of the two value (1-2= weak, 
3-4= moderate, 5-6= strong).  82% of the sample expressed RANKL >75% from whole 
stromal cell population. Base on staining intensity, 48% scored 2, and only 23% had 
maximum intensity (3). 66.6% demonstrate strong RANKL expression. The mean value 
for RANKL according to percentage of staining, staining intensity and final score was 
2.79 (SD 0.47), 1.95 (SD 0.72) and 4.77 (SD 0.99) respectively. The mean percentage 
 xviii 
staining between no recurrence and with recurrence group was significantly different 
(p=0.009). 
 
Conclusion: RANKL expression is generally high in stage III GCT and is a 
reliable prognostic markers in predicting the risk of local recurrence but not in lung 
metastasis. 
 
 
 
Prof Dr Wan Faisham Nu’man Wan Ismail: Supervisor 
Dr Md Salzihan Md. Salleh: Co-Supervisor 
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1.0 INTRODUCTION 
 
Giant Cell Tumor of the bone (GCT) is regarded as a benign locally aggressive primary 
bone tumour that carries risk for local recurrences and pulmonary metastases (Osaka et 
al., 1997; Masui et al., 1998). 
GCT of bone accounts for 4-8% of all bone tumours, however there is a usually high 
prevalence and aggressive presentations in Southern India and China, where it represents 
20% of all primary bone tumour (Turcotte et al., 2006; Arnold et al., 2011). In Malaysia, 
Faisham et al. (2006) and Ismail et al. (2010) have reported that most of cases presented 
were staged III GCT which were locally aggressive tumours and have high rate of 
metastasis to lung which range from 19.4% to 30%. The disease typically affects 
skeletally mature adults up to 40 years of age. Most of the tumours occur around the knee 
joint (50%) followed by distal radius and proximal humerus (Wullig et al., 2001). 
The typical appearance of GCT is best demonstrated on conventional radiographs which 
show a lytic lesion located at epiphyseal region that has a well defined but non sclerotic 
margin, is eccentric in location, extends to the subchondral bone, and occurs in patients 
with closed physes (Murphey et al., 2001; Turcotte et al., 2006; Arnold et al., 2011). 
There is no mineralized tumour matrix. MRI is crucial for determination of extraosseous 
extension, the marrow involvement and articular surface involvement and is important as 
part of local staging of the disease. 
Based on radiological findings, Campannaci et al. (1987) have classified GCT into 3 
stages. Stage III lesion are aggressive in nature. It shows a rapid progression of the 
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disease and is often associated with pathological fractures. The tumour has fussy borders, 
suggesting a rapid and possibly permeative growth. The tumour bulges into the soft tissue 
but the soft tissue mass does not follow the bone contour and is not limited by an 
apparent shell of reactive bone. On MRI, Stage III lesions are often characterized by 
cortical breakage and local soft tissue extension whereby in MRA (Magnetic Resonance 
Angiography) showed local increase in vascularity. Unfortunately, many authors 
including Campanacci et al. 1987 do not regard this staging system as predictive of the 
prognosis, because they found no correlation between radiography and local recurrence 
of GCT, or in other words its aggressiveness.  
 
Macroscopically, GCT presents as a hemorrhagic, soft mass eroding bone. 
Microscopically, the tumor features a usually bland stromal cell population made of 
osteoblast lineages which are considered as a neoplastic factor in GCT and a second 
population of monocytes and eponymous multinucleated giant cells that are capable for 
bone resorption. 
Numerous attempts have been made to predict the behavior of GCT of bone, however 
there has been no definitive clinical, biological or histological paramenter available that 
can give better prediction regarding the aggressiveness of the tumour in terms of potential 
for local recurrence and lung metastases (Faisham et al., 2006). 
Immunohistochemical studies give additional useful information in predicting the 
behaviour  of GCT. There are various proliferation markers such as p53, Ki- 67, PCNA, 
MMP-2 and MMP-9 (Matrix Metalloproteinase), RANKL, VEGF and recently serum 
Tartrate-Resistant Acid Phosphatase 5b that had been studied with intention to correlate 
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with the aggressiveness of GCT. 
RANKL is expressed by osteoblast lineage and become an important key effector 
molecule in promoting osteoclastogenesis, thus normal bone remodeling, whereby it 
binds with RANK on osteoclast surface membrane and trigger various intracellular 
signaling cascade and induce the differentiation of osteoclast and prolong their 
survivorship.  
Various studies had been done using immunohistochemistry, immunofluorescence, RT-
PCR assay and ex vivo stromal cells cultured confirmed that highly dense stromal cells of 
GCT expressed RANKL over the surface membrane of osteoblastic lineage. Wittrant et 
al. (2004) also found that RANKL expression is high compared to non-osteolytic bone 
tumours. However, there was no study, which evaluates and compares RANKL 
expression among GCT patient who presented with recurrence and lung metastasis. 
We evaluated 39 archived tissue specimen diagnosed with GCT stage III, for positivity of 
RANKL in hope to find its correlation with local recurrences and lung metastasis, and 
probably justify the usage of denosumab among our local population. 
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2.0 LITERATURE REVIEW  
 
2.1 Giant Cell Tumour (GCT) stage III 
 
2.1.1 Definition 
 
The World health Organization has classified GCT as “an aggressive, potentially 
malignant lesion”, which means that its evolution based on its histological features is 
unpredictable (Szendroi, 2004). It is a heterogenous tumour composed of unstable spindle 
shaped neoplastic mononuclear stromal cells and reactive components that are monocytes 
and osteoclast like giant cells. 
 
2.1.2 Epidemiology 
GCT has a significant incidence, accounting for 20% of all benign bone tumors and 5% 
of all bone tumours, however there is an unusually high prevalence in southern India and 
China, where GCT represents 20% of all primary bone tumour (Turcotte et al., 2006; 
Arnold et al., 2011).  
The natural history and behavior of GCT in Asian population was found to be more 
aggressive compared to Western population (Shih et al., 1998). In India, the incidence of 
GCT of bone was also reported to be high in the population which is about 20.3% of all 
primary bone tumours. In their series of 139 cases, they found as high as 51.1% were 
classified as Stage III GCT with 11.1% of local recurrence (Saikia et al., 2011). The most 
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recent study in Japan also found more aggressive behavior of GCT where they reported 
the incidence of lung metastasis as high as 7.5% and malignant transformation as 2.7% 
(Takeuchi et al., 2011). In Singapore, they had observed about 31% of local recurrence in 
their cases of GCT of bone (Lim and Tan, 2005). In Malaysia, Faisham et al. (2006) has 
observed that most of the cases were stage 3 GCT of bone which were locally aggressive 
tumours and more likely to metastasize to lung. In his series, about 30% of all the cases 
had pulmonary metastases. Ismail et al. (2010) has also found as high as 19.4% of 
pulmonary metastasis in his study of 39 cases. 
The tumor appears in skeletally mature individuals with its peak incidence in the third 
and fourth decade of life (Carrasco and Murray et al.,1989; Salzer-Kuntschik et al., 
1998). 80% of cases occurring between 20 and 50 years of age. Only 13% of cases occur 
in patients over the age of 50 years and less than 3% of cases occur before the age of 14 
years (Turcotte et al., 2006). GCT in patients with an open growth plate is very rare and 
accounts for 1.5% of all GCTs (Picci et al., 1983).  Although some studies show a slight 
female predominance, most support that there is no sex predilection in GCT ( Turcotte et 
al., 2006; M. Wulling et al., 2001).   
The main localization of GCT is the epiphysis of long tubular bones (Mirra et al., 1989; 
Delling et al., 1997). However, in children with open physes, GCT of bone may be 
centered in the metaphysis and may abut the physis.. Nearly 50% of cases occur in the 
region of the knee including distal femur and proximal tibia.  15% of cases have been 
reported in flat bones such as the pelvis, sacrum, spine, ribs, and skull. Less than 1% of 
cases have been reported in the scapula. GCT may occur in the skull or pelvis secondary 
to Paget disease (Hoch et al., 2007). The bones of the hands and feet are uncommon 
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locations, with a prevalence of less than 2% (Biscaglia et al., 2000). GCT of the spine 
and sacrum is rare and is reported in less than 3% of cases (Kwon et al., 2007). 
Multicentric GCT has been reported in less than 1% of cases, with lesions often located 
in the distal extremities, particularly the hands and feet. 
Statistically, 80% of GCTs have a benign course, with a local rate of recurrence of 20% 
to 50%. About 10% undergo malignant transformation at recurrence and 1% to 4% gives 
pulmonary metastases even in cases of benign histology (Szendroi, 2004). In rare 
instances about 1-3% can transform into the malignant sarcoma phenotype with equal 
disease outcome (Werner, 2006; Dickson et al., 2008). 
 
2.1.3 Pathophysiology 
 
GCT is a heterogeneous tumours that are composed of several cell types. A defining 
feature of the lesion is the presence of numerous multinucleated giant cells that are 
uniformly distributed amongst mononuclear spindle-like stromal cells and other 
monocytes. The giant cells are principally responsible for the extensive bone resorption 
by the tumour. However, the spindle-like stromal cells chiefly direct the pathology of the 
tumor by recruiting monocytes and promoting their fusion into giant cells. The stromal 
cells also enhance the resorptive ability of the giant cells (Robert et al., 2013).  
The spindle-like stromal cells are actually the neoplastic component of the tumor, owing 
to their ability to readily proliferate in culture (Goldring et al., 1987; Wulling et al., 
2003) and their capacity to form tumors in mice. Collectively, the stromal cells show 
positive expression of bone sialoprotein, osteonectin, osteopontin, osterix, and the runt-
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related transcription factor 2 (Runx2) but only occasional expression of osteocalcin. The 
stromal cells are themselves a heterogenous population and may consist of cells at 
multiple stage of differentiation including osteoblast. 
The synthesis of giant cells from hematopoietic precursors is directed by spindle-like 
stromal cells in a process that closely mirrors osteoclastogenesis. Namely, the stromal 
cells produce chemokines, including stromal cell-derived factor-1 (SDF-1) (Liao et al., 
2005) and monocyte chemoattractant protein-1 (MCP-1) (Zheng et al., 1998) that recruit 
monocytes to the tumor site. Following recruitment of monocytes, the stromal cells 
promote their proliferation and differentiation through the synthesis of macrophage 
colony-stimulating factor (M-CSF) (Atkins et al., 2000, Miyamoto et al., 2000) and 
potentially the recently- discovered interleukin (IL)-34 (Baud’huin et al., 2010), which 
act via the colony stimulating factor 1 receptor (CSF1R) expressed on the monocytes. M-
CSF also induces RANK expression on monocytes (Arai et al., 1999). Cellular fusion of 
the monocytes is initiated by RANK ligand (RANKL), which is a membrane-bound 
member of the tumor necrosis factor (TNF) superfamily and is expressed by the spindle-
like stromal cells (Atkins et al., 2000; Roux et al., 2002, Miyamoto et al., 2000,; Huang 
et al., 2000). Its expression is characteristically increased in GCT compared to controls 
(Morgan et al., 2005; Takayanagi et al., 2000), and giant cell formation begins following 
it’s binding to RANK.  
Besides that, Osteoprotegerin (OPG), a soluble decoy receptor for RANKL, is also 
expressed by the stromal cells (Atkins et al., 2001) however, its presence does not 
entirely compensate for the increased RANKL expression. 
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Indeed, the giant cells express tartrate-resistant acid phosphatase (TRAP) (Anazawa et 
al., 2006; Mii et al., 1991), cathepsin K (Drake et al., 1996), and carbonic anhydrase II 
(Zheng et al., 1993, Kotake et al., 1996), as well as many receptors that are characteristic 
of osteoclasts, including the receptor activator of nuclear factor-κB (RANK) (Atkins et 
al., 2006; Roux et al., 2002), the calcitonin receptor (Collier et al., 1998; Nicholson et al., 
1987) and the αvβ3 integrin. Moreover, the giant cells are capable of bone resorption 
(Balke et al., 2010) and may occasionally show numerous infoldings under electron 
microscopy that resemble the ruffled membrane of true osteoclasts (Kanehisa et al., 1991; 
Steiner et al., 1972). Perhaps the most significant difference between these cells and other 
osteoclasts is that the giant cells can be considerably larger, containing hundreds of nuclei  
(Zheng et al., 2001, Gupta et al., 2008). 
The giant cells express the requisite bone-resorbing components of osteoclasts: cathepsin 
K (Drake et al., 1996; Lindeman et al., 2004) which largely degrades the organic 
components of bone (Garnero et al., 1998), vacuolar H+-ATPase (V-ATPase) (Lindeman 
et al., 2004; Kotake et al., 1996; Morgan et al., 2005), which demineralizes the crystals 
of hydroxyapatite (Blair et al., 1989) and TRAP (Mii et al., 1991), which may act by 
dephosphorylating bone matrix proteins and assisting in osteoclast migration (Janckila et 
al., 2009). The presence of these enzymes suggests that giant cells resorb bone in a 
manner that is consistent with traditional osteoclasts. 
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2.1.3.1 Growth factor in stromal cells GCT 
 
As mentioned, the spindles like stromal cells are believed the neoplastic element of GCT. 
Evidence has been offered that the stromal cells in GCT are the only persisting cell type 
in cell culture (Zheng et al., 2001; Robinson et al., 1996) and able to degrade bone matrix 
either independently or synergistically with osteoclast like giant cells.  A recent report 
described cytogenetic aberrations including telomeric fusion, aneuploidy, and 
chromosome deletion in GCT stromal cells (Zheng et al., 1999) which further suggesting 
that telomere instability may participate in the development of GCTs. 
Given these numerous genetic alterations, the status of the p53 tumor suppressor and 
other cell cycle regulators may also contribute to the progression of GCTs. Wu et al. 
reported that p53 is commonly mutated in GCTs. In contrast, other analyses have 
suggested that p53 is typically not mutated in primary lesions (de Souza et al., 1999, 
Osaka et al., 2004) although there is evidence indicating mutations in stromal cell p53 
may be correlated with local recurrence, malignant transformation, and metastasis of the 
tumor (Masui et al., 1998, Gong et al., 2012). 
Besides genetic abnormality, stromal cells also produce various growth factor for 
promoting recruitment of monocytes thus formation of giant cells which later contribute 
to resorptive capacity of osteoclast like giant cells and determine the aggressiveness of 
the tumour. Examples of the chemokines produce are stromal cell-derived factor-1 (SDF-
1) (Liao et al., 2005) and monocyte chemoattractant protein-1 (MCP-1) (Zheng et al., 
1998) that recruit monocytes to the tumor site and aforementioned RANKL. 
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Study done by Knowles et al; 2008, showed that higher expression of VEGF by stromal 
cells induce by local hypoxia, which induces angiogenesis from existing vasculature and 
resulrs in the formation of numerous small blood cells that are lined by CD31 and CD34-
positive endothelial cells (Zheng et al., 2000). This VEGF could initiate a positive 
feedback loop of (pre)-osteoclast recruitment and act in an autocrine manner to enhance 
the pro-osteoclastogenic phenotype. 
Additionally, numerous MMPs have been identified within GCTs, including MMP-2 and 
MMP-9, MMP-13, MMP-1, MMP-3, MMP-4, and multiple cathepsins. Despite the 
multitude of MMPs expressed within GCT, there is little actual evidence pertaining to 
any specific roles within the tumor. It is known that MMP-2 expression is correlated with 
the vascular fraction of the tumor (Strauss et al., 2004), and MMP-9 may participate in 
vascular invasion by the giant cells (Ueda et al., 1996). However, given the established 
functions for cathepsins and MMPs in tumor angiogenesis, normal bone resorption, and 
osteoclastogenesis, it is likely that they perform similar tasks in GCT and actively 
participate in the resorption process by giant cells and may play a central role in 
catabolism of extracellular matrix macromolecules. Study by Ghert et al; 2007 suggest 
that the stromal cells produce the matrix degrading proteases MMP-2 and MMP-9, and 
these proteolytic factors are active in vitro and concluded that the stromal cells may 
therefore play a central role in degradative processes responsible for osteolysis in GCT of 
bone. 
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Plate 1: Schematic representation of GCT indicating expression of multiple key 
components by the spindle-like stromal cells, the monocytes, and the multinucleated 
giant cells. Proteins are either secreted factors (e.g. VEGF), membrane-associated 
proteins (e.g. RANK), or nuclear/cytoplasmic proteins (e.g. Runx2). Those proteins 
written in italics denote occasional expression by that cell type. Adopted from Robert et 
al., 2013. 
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2.1.4 Clinical Presentation 
The main clinical symptoms are non-specific, local swelling, warmth, and pain radiating 
independently of weight bearing (Szendroi, 2004). Even more rarely, the disease is 
discovered radiographically in the absence of symptoms.  
Pain may be activity related or experienced at rest or at night. Activity related pain is 
caused by the loss of structurally important bone and mechanical failure of bone as the 
result of the presence of the tumor. Pain at rest or at night is the result of tumor growth, 
tumor-related expansion of the periosteum, and the response of the periosteum to the 
threat of the advancing neoplasm. The duration of symptoms varies between two to six 
months and by then, in one-third of cases, the size of the tumour exceeds 50% of the 
diameter of the affected bone, it has destroyed the cortical bone and reached the 
subchondral region (Kevin et al., 2013). Pathological fracture is the first sign in 
approximately 15% of cases (Dreinfhofer et al., 1995). GCT is usually a solitary lesion 
however 1-2% may be multicentric. The common sites of involvement are distal femur, 
proximal tibia and distal radius. Other less common sites are the sacrum, the distal tibia, 
proximal femur and proximal fibula. Involvement in the spine and sacrum, and the 
compression of nerve root by the tumour may cause intense radicular pain and 
neurological deficit. 
Physical examination usually reveals an area of direct tenderness to palpation, soft tissue 
swelling over the affected area. The extension into the joint is unusual but if there is 
extension to the joint, it will lead to joint effusion, joint deformity and decreased range of 
motion. Patients often demonstrate an antalgic gait that favors the affected side. 
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GCT is usually a solitary lesion, however approximately 1% of cases present as multiple 
synchronous or metachronous lesions (K. F. Taylor et al., 2003). Most multifocal GCTs 
are synchronous and 68% of cases of multicentric giant cell tumor occur in less than 4 
years from the initial lesion treatment (A. Haskell, 2003). They have a more aggressive 
course, including an increased incidence of pathologic fractures  (B. W. Hindman, 1994) 
In our centre, most of the patients presented late without any symptoms until aggressive 
breached of the cortex and may sometimes be dormant for a period of time (Faisham et 
al., 2006) consistent with findings by Ng et al., 2002 whereby 46% of their patients 
presented late with extensive involvement of soft tissue and articular surface and 
substantial proportion of patients seek traditional means of treatment before medical 
consultation. 
 
Plate 2 : Photograph of Patient With Giant Cell Tumour of Distal Radius 
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2.1.5 Radiographic Appearance 
 
The typical appearance of GCT is best demonstrated on conventional radiographs which 
show a lytic lesion located at epiphyseal region of long tubular bones with a preference 
for the distal femur and proximal tibia, that has a well defined but non sclerotic margin, is 
eccentric in location, extends to the subchondral bone, and occurs in patients with closed 
physes (Murphey et al., 2001; Turcotte et al., 2006, Arnold et al., 2011). There is no 
mineralized tumour matrix. 
GCT may also have aggressive features, such as a wide zone of transition, cortical 
thinning, expansile remodeling, or even cortical bone destruction and an associated soft-
tissue mass (Murphey et al., 2001). These features may be more common in small-caliber 
long bones, such as the fibula or ulna, and pathologic fracture or periosteal reaction may 
occasionally complicate the diagnosis (Murphey et al., 2001).  
Although GCT is typically included in the differential diagnosis for an epiphyseal lesion, 
there is evidence that it arises in the metaphysis and extends into the epiphyseal region 
after physeal closure (Campanacci et al., 1987, Mirra 1989). For instance, in rare cases 
affecting pediatric patients, the tumor is centered within the metaphyseal region. In cases 
of multifocal GCT, lesions may occur in the metaphysis or even the diaphysis. There are 
no reported cases in which GCT has extended from the metaphysis into the epiphysis 
across an unfused physis (Murphey et al., 2001) 
The radiographic features of GCT at sites other than the long bones are nonspecific and 
not unlike those of other osteolytic processes. Giant cell tumor of the spine almost always 
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begins in the vertebral body and may lead to vertebral collapse or extend into the 
intervertebral disc, adjacent vertebral body, spinal canal or paraspinal soft tissues (Dahlin 
et al., 1997) Sternal and sacral lesions are osteolytic and owing to a large size and a soft 
tissue component, may simulate the appearance of a malignant neoplasm. In the sacrum, 
the eccentric location and abutting of the SI joint differentiate GCT from similar 
appearing sacral chordomas. In the sacrum transarticular extension of the tumor may be 
noted. 
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Plate 3: Radiographic Image of Giant Cell Tumour of Proximal Tibia, which describe 
expansile lytic lesion over metaphyseal area with subchondral extension and cortical 
breach. 
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2.1.6 Computed Tomography 
 
Plain radiographs remain the mainstay of the diagnosis of GCT, however, MRI and CT 
are important for staging and therefore surgical planning. CT will rarely add additional 
information that changes the differential diagnosis (Moser et al., 1990). However, CT is 
superior to conventional radiography and tomography in outlining tumor extent, 
especially its extra-osseous portion and its relationship to adjacent structures, as well as 
evaluation of cortical integrity and determination of tumor recurrence (Hudson et al., 
1984). The expanded and thinned cortex is vividly demonstrated and the presence or 
absence of matrix calcification can be assessed. Fluid levels may be seen (Resnik et al., 
1986) secondary to an aneurysmal bone cyst component or due to intratumoral 
hemorrhage. Reactive changes and edema on the outer cortical surface or the synovium 
may mimic tumor extension. The axial slices provided by CT do not allow accurate 
evaluation of the subarticular cortex because of volume averaging. 
The advent of color volume rendered three-dimensional (3D) CT with video files allows 
evaluation of multiple tissues at the same time. The spatial depiction of the tumor along 
with surrounding anatomical relationships such as vessels and ureter make this a useful 
preoperative imaging modality in cases of pelvic GCT. Manipulation and rotation of the 
3D images through 360 degrees allows the surgeon a better understanding of the extent of 
the mass and anticipated surgical complexities (Shaligram et al., 2007).  
 
Although CT angiography is seldom used as a diagnostic modality in the era MRI, it can 
determine the extra- osseous extent of tumour and its relationship to major vessels. The 
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role of angiography today, in patients with GCT is limited to a study of regional vascular 
anatomy and perhaps, preoperative transcatheter arterial embolization to facilitate 
excision and decrease surgical blood loss or in instance of unresectable neoplasm 
(Shaligram et al., 2007; Chuang et al., 1981). 
 
2.1.7 Magnetic Resonance Imaging 
 
MRI is currently the best imaging modality for GCT because of its superior contrast 
resolution and multiplanar imaging capabilities that allow accurate tumor delineation 
(Moser et al., 1990). MRI is useful in determining extraosseous extent and articular 
surface involvement (Hermann et al., 1987), however subtle cortical destruction is better 
demonstrated by CT. MRI is also useful in assessing intraosseous and intramedullary skip 
lesions GCT shows low intensity on T1 and heterogeneous high intensity on T2 weighted 
images. Therefore intramedullary tumor is best seen on T1W, while its extraosseous 
portion is best appreciated on T2W images (Brady et al., 1982) 
The hypervascular stroma contains sinusoidal vessels that predispose to hemorrhage 
(Aoki et al., 1991). The phagocytosed erythrocytes lead to iron deposition in the form of 
hemosiderin (Aoki et al., 1991).  Giant cell tumors often have extensive hemosiderin 
deposition within tumor tissue, resulting in very low signal intensity on all pulse 
sequences (Aoki et al., 1991). This is seen in up to 60% of cases (Aoki et al., 1991).  
Low signal areas may also be due to collagen deposition secondary to surgery or trauma 
(Aoki et al., 1991). Gadolinium enhancement reveals areas of hypervascularity and 
enhancement with a very heterogeneous signal pattern (Resnik et al., 1988). 
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MRI become important tool to detect giant cell tumour which undergoes malignant 
spontaneous transformation and to evaluate tumour which is located in the spine and 
sacrum where it helps to detect soft tissue extension such as compression to the spinal 
cord and nerve root (Turcotte et al., 1990; Randall, 2003). Besides that, MRI is the 
optimum technique for evaluation of recurrent or residual disease. Local postoperative 
high signal within the surgical bed that exhibits a rounded mass-like appearance with 
eccentric growth is highly suggestive of tumor (Lee et al., 1998). 
Magnetic resonance angiography (MRA), a newer and noninvasive technique, is used in 
addition to preoperative magnetic resonance imaging. Magnetic resonance angiography 
has the potential to replace conventional angiography in preoperative evaluation of 
upper-extremity tumours (Swan et al., 1993). The anatomy represented gives information 
equivalent to conventional angiography. It provides a complete preoperative evaluation 
of a tumour bed or donor site for a vascularized graft harvest (Swan et al., 1993). 
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Plate 4 : MRI Image of Aggressive Giant Cell Tumour of Distal Femur showing articular 
and soft tissue extension. 
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2.1.8 CT Thorax 
 
CT Thorax is important for the staging of GCT particularly screening for pulmonary 
metastases. It is also used as a baseline for subsequent comparison in search for 
pulmonary metastases (McKenzie, 1997).  
 
2.1.9 Radionuclide Scintigraphy (Bone Scan) 
 
GCT produces increased uptake of technitium-99m radiopharmaceuticals previously used 
to stage the GCT based on Campannaci classification. Bone scan can identify the latent, 
active and aggressive based on hot spot on bone scan. The pattern of increased uptake 
may be diffuse (40%) or peripheral with little central activity (60%) (Van et al., 1986). 
Extended patterns of radioactivity uptake beyond the margins of the tumor preclude 
accurate definition of intramedullary extent (Hudson et al., 1984). Increase uptake in the 
bone across the adjacent joint and in the joints of the same extremity not involved by 
tumour may occur (Gudmundsson et al., 1984). Therefore the role of bone scan in GCT is 
limited because it is nonspecific and unreliable in defining the extent of the tumour (Van 
et al., 1986). It is however, helpful in evaluating the rare patient with multicentric or 
metastatic GCT.  
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2.1.10 Gross Pathology 
 
GCT of the bone involved epiphyseal-metaphyseal region of long bones (Goldring et al., 
1987). Grossly, the tumour is grey to reddish brown in colour and it is composed of soft, 
vascular and friable tissue. The unaltered lesional tissue appears rather homogeneous, 
with a tan colour and a moderately firm consistency. Firmer grey-yellow areas of fibrous 
and collagenization and osteoid production may be found as a result of previous fracture 
and degeneration. However, foci of hemorrhage or necrosis may be observed in many 
tumours. The overlying cortex usually undergoes resorption and the contour of the bone 
is expanded by the tumour which is covered by thin shell of subperiosteal new bone 
(Goldring et al., 1987). 
 
2.1.10 Histology 
 
Giant cell tumor consists of three cell types: two mononuclear cells and the 
multinucleated, osteoclast like giant cells. The mononuclear cells are composed of a 
round and a spindle shaped cell type. The round cells have an oval nucleus with a central, 
prominent nucleolus. The spindle-shaped, fibroblast-like cells are characterized by a 
longitudinal often cigar-shaped nucleus. In some areas of the tumor the spindle-shaped 
cells are more prominent, showing a scattered fibrous background or storiform pattern. In 
these areas a reduced number of giant cells can be observed (Mirra 1989).  
The number of multinucleated giant cells varies between different cases. In addition, the 
number of nuclei within the giant cells shows a broad variation from 5 to over 100 nuclei 
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(Delling 1997). The nuclei seemed to be identical to those in the round to oval cell types 
(Mirra 1989; Unni 1996). Mitotic figures are never seen in the giant cells. Presence of  
atypical mitoses may suggest malignant transformation.  
Regressive changes like fibrosis, foam cell formations, and hemosiderin depositions can 
also be detected in some GCTs (Mirra 1989). Areas of infarct like necrosis are also 
common (Unni 1996). Occasionally, reactive bone formations as well as tumor osteoid 
formations are present (Mirra 1989). Various amounts of osteoid were found in 31% of 
the tumors, while reactive bone formations, especially in the periphery of the lesion, 
could be seen in 59% of the cases (M.Wulling et al., 2001). According to the local 
aggressive behavior of GCT, soft tissue extension is not an uncommon finding. In 
addition, multinucleated giant cells may be detectable within or penetrating the vascular 
lumina (Osaka et al., 1997), but these findings do not seem to correlate with an increased 
risk of metastasis (Mirra 1989; Unni 1996). In 23% of tumors, giant cells were found in 
blood vessels (M. Wulling et al., 2001). Metastasis of GCT occurs in 2% to 9% of large 
series (Bertoni et al. 1988; Kay et al. 1994). 
Owing to the complex histological composition of GCT, differential diagnosis is required 
to exclude the diagnosis of other lesions also containing giant cells, such as variants of 
aneurysmal bone cysts, fibrous metaphyseal defects, chrondroblastoma, brown tumor in 
hyperparathyroidism, as well as giant-cell-rich variants of osteosarcoma.  
To confirm the diagnosis, immunohistochemical analysis may be performed however it 
not part of routine investigation, only in highly suspicious of giant cell rich osteosarcoma 
and giant cell sarcoma. Giant cells constantly express CD68, an antigen expressed by 
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macrophages and osteoclasts, as well as p63. However, although sensitive to detection, 
p63 is not specific and can be expressed in other giant-cell-containing lesions of bone, 
specifically primary aneurysmal bone cysts, chondroblastomas, giant-cell reparative 
granulomas and some osteosarcomas (Doussis et al., 1992; Dickson et al., 2008).  
2.1.11 Classification and Staging 
 
Multiple classifications were develop to stage GCT. Jaffe et al 1940 grade GCT based on 
histological appearance of the stromal cells and the number of giants cells and mitoses, 
whereas Dahlin in 1949 distinguished only benign, aggressive and malignant. The 
histological staging system of Jaffe and its prognostic value of this grading had been 
disputed. Sanerkin et al., 1980 found no correlation between aggressiveness of the 
tumour and the histological grade. Thus, the prediction of the clinical behaviour of GCT 
based on its histological features is impossible. 
Later on, Enneking 1986 and Campanacci 1987 classified GCT based on their clinical 
and radiographic features According to this system, there are three stages: 
Stage 1: Benign, latent giant cell tumours. These lesions are characterized by a static 
pattern of growth, without features of local aggressiveness. They have well-margin 
border of a thin rim of mature bone. The cortex is intact or slightly thinned but nor 
deformed. 
Stage 2: Benign, active giant cell tumours. These lesions are often clinically 
symptomatic. Plain radio- graphs, bone scans, computerized tomographic scans and 
magnetic resonance images demonstrate expansile radiolucent lesions, which frequently 
